Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma

Purpose of investigation: To report the experience of a single institution in the south of Israel with gemcitabine in heavily pretreated patients with platinum-resistant recurrent ovarian, peritoneal and fallopian tube carcinoma.

Methods: The hospital records of 21 patients with ovarian, peritoneal and fallopian tube carcinoma who had salvage chemotherapy with gemcitabine between October 1998 and November 2003 were retrospectively reviewed. Gemcitabine, 1000 mg/m2, was given on days 1, 8, and 15 of every 28 days. Dose intensity and relative dose intensity of gemcitabine were calculated. Response was determined using clinical evaluation, radiological reports and CA-125 level. Toxicity was graded using the National Cancer Institute (NCI) criteria.

Results: The median relative dose intensity of gemcitabine received by the patients was 0.91, with 17 (81%) patients receiving more than 80% of the planned standard dose intensity. Two (9.5%) patients had complete response of disease lasting for ten and 33 months, respectively, eight (38.1%) had stable disease and 11 (52.4%) had progressive disease. Three (14.3%) patients had CA-125 complete response, five (23.8%) had CA-125 partial response, six (28.5%) had CA-125 stable levels and seven (33.3%) had CA-125 progressive levels. Toxicity was mainly hematological with grade 3-4 toxicity as follows: leukopenia--two (9.5%) patients, neutropenia--four (19%), thrombocytopenia--three (14.3%) and anemia--one (4.7%).

Conclusion: Gemcitabine has some activity and low and well tolerated toxicity in heavily pretreated patients with platinum-resistant recurrent ovarian, peritoneal and fallopian tube carcinoma.

Ovarian carcinoma; Chemotherapy; Gemcitabine; CA-125; Toxicity

[1] McGu订e W.P., Ozols R.F.: "Chemotherapy of advanced ovarian cancer". Semin. Oneal., 1998, 25, 340.

[2] Lund B., Hansen O.P., Neijt J.P., Theilade K., Hansen M.: "Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients". Anticancer Drugs, 1995, 6 (suppl. 6), 61.

[3] Shapiro J.D., Millward M.J., Rischin D., Michael M., Walcher V., Francis P.A. et al.: "Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel". Gynecol. Oneal., 1996, 63, 89.

[4] Friedlander M., Millward M.J., Bell D., Bugat R., Harnett P., Moreno J.A. et al.:''A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer". Ann. Oncol., 1998, 9, 1343.

[5] von Minckwitz G., Bauknecht T., Visseren-Grul C.M., Neijt J.P.: "Phase II study of gemcitabine in ovarian cancer". Ann. Oncol., 1999, 10, 853.

[6] Silver D.F., Piver M.S.: "Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum". Am. J. Clin. Oncol., 1999, 22, 450.

[7] Coenen M., Berteloot P., Amant F., Vangramberen M., Vergote I.: "Gemcitabine in platin-paclitaxel resistant ovarian carcinoma". In: Program/Proceedings of the 36'" Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May 20-23, 2000, Abstract No. 1603.

[8] Markman M., Webster K., Zanotti K., Kulp B., Peterson G., Belinson J.: "Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer". Gynecol. Oncol., 2003, 90, 593.

[9] Bilgin T., Ozalp S., Yalcin O.T., Zorlu G., Vardar M.A., Ozerkan K.: "Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients". Eur. J. Gynaecol. Oneal., 2003, 24, 169.

[10] D'Agostino G., Amant F., Berteloot P., Scambia G., Vergote I.: "Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer". Gynecol. Oncol., 2003, 88, 266.

[11] Levin L., Hryniuk W.M.: "Dose intensity analysis of chemotherapy regimens in ovarian carcinoma". J. Clin. Oncol., 1987, 5, 756.

[12] Levin L., Hryniuk W.M.: "The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer". Semin. Oncol., 1987, 14 (suppl. 4), 12.

[13] Hansen S.W.: "Gemcitabine in the treatment of ovarian cancer". Int. J. Gynecol. Cancer, 2001, I 1 (suppl. I), 39.

[14] Common Terminology Criteria for Adverse Events, Version 3.0, Revised June 10, 2003, National Cancer Institut e, http://ctep.cancer.gov/forms/CTCAEv3. pdf.

[15] Cesano A., Lane S.R., Poulin R., Ross G., Fields S.Z.: "Stabilization of disease as a useful predictor of survival following secondline chemotherapy in small cell lung cancer and ovarian cancer patients". Int. J. Oncol., 1999, 15, 1233.

[16] Nielsen H.A., Nielsen D., Engelholm S.A.: "Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer". Gynecol. Oneal., 2000, 77, 383.